Drug Profile
CKD 702
Alternative Names: CKD-702Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Developer Chong Kun Dang; National Cancer Center (Korea)
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Epidermal growth factor receptor antagonists; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastric cancer
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (IV, Infusion)
- 01 Dec 2022 Phase-II clinical trials in Gastric cancer (Combination therapy, Second-line therapy or greater) in South Korea (IV) (NCT05750290)
- 09 Sep 2022 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Non-small cell lung cancer presented at 47th European Society for Medical Oncology Congress (ESMO-2022)